Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04040049 · ClinicalTrials.gov registry record · Phase 1
A Fabry Disease Gene Therapy Study
A Phase 1 study, sponsored by Spur Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT04040049 is a Phase 1 study that was terminated before completion, run by Spur Therapeutics. The registered enrollment target is 3 participants.
The verdict
NCT04040049, a Phase 1 study, was terminated before completion, sponsored by Spur Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a multinational, open-label study to assess the safety and efficacy of FLT190 in up to 15 adult male participants with classical Fabry disease.
Interventions
- GENETIC FLT190
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-07-08 |
| Est. Completion | 2023-05-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04040049
The ClinicalTrials.gov registry entry for NCT04040049 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spur Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FLT190 is the first listed.
NCT04040049 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04040049 about?
NCT04040049 is a clinical study titled "A Fabry Disease Gene Therapy Study". This is a multinational, open-label study to assess the safety and efficacy of FLT190 in up to 15 adult male participants with classical Fabry disease.
What is the current status of trial NCT04040049?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2019-07-08. Estimated completion is 2023-05-02.
What interventions are being tested in trial NCT04040049?
The interventions under investigation include: FLT190 (GENETIC).
Who is sponsoring clinical trial NCT04040049?
This trial is sponsored by Spur Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.